Skip to content
Screener

Taysha Gene Therapies, Inc. TSHA Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue-
EPS-$0.12Miss by $0.02
EPS estimate-$0.10

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$755.6K
EPS estimate-$0.14

Financials

Q1 2026

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.28B+351%
Enterprise value$1.08B+368%
P/S171.9×+132×

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

FAQ

When did Taysha Gene Therapies, Inc. report Q1 2026 earnings?
Taysha Gene Therapies, Inc. (TSHA) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Taysha Gene Therapies, Inc.'s Q1 2026 revenue and EPS?
Taysha Gene Therapies, Inc. reported revenue of - and eps of $-0.12 for Q1 2026.
Did Taysha Gene Therapies, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.10 by $0.02.
How did Taysha Gene Therapies, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $2.3M a year earlier and eps declined 50.0% from $-0.08.
Where can I find Taysha Gene Therapies, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-207633) and the 10-Q periodic report (0001193125-26-207666) directly on SEC EDGAR. The filing index links above go to sec.gov.